Subscribe
shutterstock_1969624816_frankhh
FrankHH / Shutterstock.com
1 February 2022

IP waiver won’t solve vaccine problems, warn experts

A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization (WTO) failing to reach consensus.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
COVID-19 IP waiver faces uncertain future
31 March 2022   The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa.
Big Pharma
US, EU, India and South Africa reach COVID waiver ‘compromise’
16 March 2022   The US, EU, India and South Africa have reached an undisclosed agreement related to the stonewalled COVID-19 vaccine IP waiver.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
COVID-19 IP waiver faces uncertain future
31 March 2022   The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa.
Big Pharma
US, EU, India and South Africa reach COVID waiver ‘compromise’
16 March 2022   The US, EU, India and South Africa have reached an undisclosed agreement related to the stonewalled COVID-19 vaccine IP waiver.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

More on this story

Americas
COVID-19 IP waiver faces uncertain future
31 March 2022   The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa.
Big Pharma
US, EU, India and South Africa reach COVID waiver ‘compromise’
16 March 2022   The US, EU, India and South Africa have reached an undisclosed agreement related to the stonewalled COVID-19 vaccine IP waiver.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB